SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that…
Biotechnology
US, Stamford [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer Group
Configuration
| Company | Price d* | Change d* | Volume, Avg. k, d* | Market Cap. d* | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding d* | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 13,470.40 | 862.30 | 210.39 | -82.56 | 39.40 | 0.00 | 19.6456 | -0.38 | -1.0918 | -24.1572 | -0.09 | -0.08 | 7.6175 | - - | ||
| Maximum | - - | - - | - - | 458,604.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.01 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| SpringWorks Therapeutics, Inc. SWTX | 36.45 | -0.10 -0.27% | 3,512 vs. 986 | 2,711.00 | 21.00 | -87.00 | -79.00 | -982.00 | -1.1800 | -10.0500 | 0.0000 | 0.9081 | -4.1600 | -0.1540 | -0.1330 | 6.5602 | 74.00 | ||
| Mirati Therapeutics, Inc. MRTX | 58.70 | -0.10 -0.17% | 20,956 vs. 1,778 | 4,117.00 | 16.00 | -161.00 | -143.00 | -2,976.00 | -2.4900 | -4.3716 | 0.0000 | 0.9129 | -9.8722 | -0.1711 | -0.1433 | 7.2541 | 70.00 | ||
| Revolution Medicines, Inc. RVMD | 55.13 | -2.24 -3.90% | 1,944 vs. 1,156 | 9,273.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 168.00 | ||
| Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 | ||
| Blueprint Medicines Corporation BPMC | 88.69 | -6.96 -7.28% | 982 vs. 601 | 5,634.00 | 96.00 | 89.00 | -102.00 | -2,250.00 | 1.4500 | 16.6530 | 0.0000 | 0.9168 | 0.9274 | 0.2869 | 0.0858 | 3.4266 | 63.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 26.27 | -1.79 -6.38% | 5,504 vs. 2,493 | 3,267.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.